7 results on '"Andrac-Meyer, L."'
Search Results
2. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
- Author
-
Charpin-Taranger C, Claude Allasia, Charafe-Jauffret E, David Jérémie Birnbaum, Séverine Carpentier-Meunier, Jean-Philippe Dales, Pascal Bonnier, Lavaut Mn, Stéphane Garcia, Andrac-Meyer L, and Jocelyne Jacquemier
- Subjects
Cancer Research ,medicine.medical_specialty ,Pathology ,C-Met ,Immunocytochemistry ,Breast Neoplasms ,Biology ,chemistry.chemical_compound ,Automation ,Phosphatidylinositol 3-Kinases ,Breast cancer ,immunocytochemistry ,image analysis ,medicine ,skin and connective tissue diseases ,Molecular Diagnostics ,c-Met ,Tissue microarray ,tissue microarray ,Anatomical pathology ,Proto-Oncogene Proteins c-met ,medicine.disease ,Cadherins ,Immunohistochemistry ,Oncology ,chemistry ,Tissue Array Analysis ,Cancer research ,Breast carcinoma ,Inflammatory Breast Carcinoma - Abstract
Inflammatory breast carcinoma (IBC) is a rare but aggressive tumour associated with poor outcome owing to early metastases. Increased expression of c-Met protein correlates with reduced survival and high metastatic risk in human cancers including breast carcinomas and is targetable by specific drugs, that could potentially improve the prognosis. In the present study, we compared c-Met expression in IBC (n=41) and non-IBC (n=480) immunohistochemically (Ventana Benchmark autostainer) in two tissue microarrays (TMA) along with PI3K and E-cadherin. The results were quantified through an automated image analysis device (SAMBA Technologies). We observed that (i) c-Met was significantly overexpressed in IBC as compared with non-IBC (P
- Published
- 2007
3. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
- Author
-
Garcia, S, primary, Dalès, J-P, additional, Jacquemier, J, additional, Charafe-Jauffret, E, additional, Birnbaum, D, additional, Andrac-Meyer, L, additional, Lavaut, M-N, additional, Allasia, C, additional, Carpentier-Meunier, S, additional, Bonnier, P, additional, and Charpin-Taranger, C, additional
- Published
- 2007
- Full Text
- View/download PDF
4. New fat-derived products for treating skin-induced lesions of scleroderma in nude mice.
- Author
-
Serratrice N, Bruzzese L, Magalon J, Véran J, Giraudo L, Aboudou H, Ould-Ali D, Nguyen PS, Bausset O, Daumas A, Casanova D, Granel B, Andrac-Meyer L, Sabatier F, and Magalon G
- Subjects
- Animals, Cells, Cultured, Female, Humans, Mice, Mice, Nude, Neovascularization, Physiologic, Sclerosis therapy, Skin blood supply, Adipose Tissue cytology, Mesenchymal Stem Cell Transplantation, Platelet Transfusion, Skin pathology, Skin Diseases therapy
- Abstract
Introduction: Scleroderma is characterized by cutaneous manifestations that mainly affect the hands, arms and face. As of today, there is no treatment for fibrotic skin lesions of scleroderma. Previously we generated and validated a model of scleroderma-like skin sclerosis in nude mice, appropriate to inject human derived products. We showed that the subcutaneous injection of micro-fat (MF), purified and injected using small caliber cannulas, have anti-fibrotic and pro-angiogenic effects and appears more suitable for the treatment of skin lesions of scleroderma compared to the gold standard (Coleman's technique or macro-fat). Here we compared the long-term efficacy of micro-fat "enriched" with other therapeutic products including the stromal vascular fraction (SVF) of fat and platelet-rich plasma (PRP) from blood in our murine model of scleroderma., Methods: We used 72 nude mice in this study. We formed six experimental groups: Macro-fat, MF, SVF, PRP, MF + SVF, MF + PRP. This project has three phases: i) Induction of skin sclerosis by daily subcutaneous injections of bleomycin (BLM) for 4 weeks in nude mice; ii) Purification and injection of the different cell therapy products; iii) Histological analyses done 8 weeks post-injections., Results: MF + SVF and MF + PRP significantly reversed dermal and epidermal sclerosis (P <0.01). Macro-fat, SVF, PRP only corrected the dermal sclerosis (P <0.05). Epidermal sclerosis was reduced in treatments containing MF (P <0.01). MF was more stable. Products containing the SVF were associated with a significant increase of the local vascularization (P <0.01)., Conclusions: All tested substances were effective in treating skin-induced lesions of scleroderma with different levels of fibrosis and vascular improvement; MF derived products are more stable and SVF demonstrated better pro-angiogenic effects. The observed efficacy of this combination of products in the animal model provides a rationale for potential clinical applications to treat human disease.
- Published
- 2014
- Full Text
- View/download PDF
5. [High-throughput quantification of tissue microarrays: identification of candidate target proteins in inflammatory breast cancer].
- Author
-
Taranger-Charpin C, Andrac-Meyer L, Dales JP, Carpentier-Meunier S, Andonian C, Lavaut MN, Allasia C, and Bonnier P
- Subjects
- Adenocarcinoma metabolism, Adenocarcinoma mortality, Adenocarcinoma pathology, Adult, Biopsy, Breast pathology, Breast Neoplasms metabolism, Breast Neoplasms mortality, Breast Neoplasms pathology, Cadherins metabolism, Densitometry, Female, Focal Adhesion Kinase 1, Humans, Immunohistochemistry, Phenotype, Adenocarcinoma genetics, Breast Neoplasms genetics, Proto-Oncogene Proteins c-met metabolism, Tissue Array Analysis
- Abstract
Inflammatory breast carcinoma (IBC) is a rare but very aggressive tumour phenotype. Increased c-Met protein expression correlates with reduced survival and a higher metastatic risk in many human malignancies, including breast cancer Several studies have shown that c-Met protein is targetable by specific drugs. Here we compared c-Met expression in IBC (n = 41) and non IBC (n = 480). Two microarrays of IBC and non IBC tissues were constructed and standardized. C-Met, P13K and E-cadherin were immunodetected (Ven-tana Benchmark Autostainer) on serial sections. The results were quantified with an automated image analysis device (SAMBA Technologies) by immunoprecipitate densitometry of each core section (0.6 microns thick). We found that (i) c-Met is significantly overexpressed in IBC compared to non IBC (p < 0. 001), (ii) P13K is also overexpressed (p < 0.001) in IBC, suggesting that overexpressed c-Met is functionally active, at least through the PI3K signal transduction pathway ; and (iii) E-cadherin is paradoxically overexpressed in IBC. We conclude that c-Met may constitute a target for specific therapy in patients with poor-prognosis malignancies like IBC Automated image analysis of TMA is a valuable tool for high-throughput quantification of the immunohistochemical expression of the tumor proteome.
- Published
- 2007
6. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
- Author
-
Charpin-Taranger C, Dales JP, Garcia S, Andrac-Meyer L, Ramuz O, Carpentier-Meunier S, and Bonnier P
- Subjects
- Adult, Aged, Aged, 80 and over, Antigens, CD, Breast Neoplasms blood supply, Breast Neoplasms mortality, Breast Neoplasms pathology, Endoglin, Endothelium, Vascular chemistry, Endothelium, Vascular pathology, Female, Follow-Up Studies, Humans, Life Tables, Lymphatic Metastasis, Middle Aged, Neoplasm Metastasis, Neovascularization, Pathologic metabolism, Prognosis, Proportional Hazards Models, Receptors, Cell Surface, Risk, Survival Analysis, Biomarkers, Tumor analysis, Breast Neoplasms chemistry, Neoplasm Proteins analysis, Vascular Cell Adhesion Molecule-1 analysis
- Abstract
The quantification of angiogenesis in human solid tumors has been shown to be an indicator of prognosis and tumor microvasculature is a candidate target for antiangiogenic therapy. CD105 (endoglin) is significantly expressed in activated endothelial cells in culture and in tumor microvessels. Quantification of CD105 immunocytochemical expression that may be of significant clinical relevance, has not been accurately evaluated as yet. In the present report, CD105 expression on frozen sections was investigated using immunohistochemical assays in a series of 929 patients and correlated with long-term (median = 11.3 years) follow-up. The CD105 immunostaining was observed on endothelial cells mostly in small cells. The number of vessels and the immunostained surface were evaluated in so called "hot spots" within tumor stroma. Both the number of vessels and immunostained surface were correlated to the patients' outcome (overall survival, disease free survival, metastases) in the whole group of patients and also specifically in node negative subgroup. Univariate (Kaplan Meier) analysis showed that the number of CD105 positive microvessels (cut-off n = 15) was significantly correlated with poor overall survival, among all patients (p = 0.001). This correlation was less significant in the group of node negative patients (p = 0.035). Marked CD105 expression was also correlated with high metastasis risk among all patients (p = 0.006) and among node negative patients as well (p = 0.001). In multivariate analysis (Cox model) CD105 immunodetection was identified as an independent prognostic indicator. Our results suggest that CD105 immunohistochemical expression has a practical clinical relevance for identifying node negative patients with poor prognosis. Moreover, the CD105 immunodetection may also be considered as a potential tool for selecting patients that could benefit from specific antiangiogenic therapy, using anti CD105 conjugates.
- Published
- 2003
7. Two cases of intravascular lymphomatosis disclosing with hypopituitarism.
- Author
-
Schleinitz N, Bernit E, Mazodier K, Charbonnier A, Horchowski N, Andrac-Meyer L, Veit V, and Harlé JR
- Subjects
- Aged, Fatal Outcome, Female, Humans, Hypopituitarism complications, Lymphoma, Large B-Cell, Diffuse complications, Male, Vascular Neoplasms complications, Hypopituitarism diagnosis, Lymphoma, Large B-Cell, Diffuse diagnosis, Vascular Neoplasms diagnosis
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.